Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease

Theodore K Marras; Mariam Hassan; Kevin C Mange; Monika Ciesielska; Shilpa Dhar Murthy; Zhanna Jumadilova; Anjan Chatterjee

doi:10.1183/23120541.00623-2021

Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease

ERJ Open Res. 2022 Jul 11;8(3):00623-2021. doi: 10.1183/23120541.00623-2021. eCollection 2022 Jul.

Authors

Theodore K Marras¹, Mariam Hassan², Kevin C Mange², Monika Ciesielska², Shilpa Dhar Murthy², Zhanna Jumadilova², Anjan Chatterjee²

Affiliations

¹ Dept of Medicine, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada.
² Insmed Incorporated, Bridgewater, NJ, USA.

Abstract

Marraset al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D.